Enbrel (Etanercept) - Summary

ENBREL SUMMARY

ENBREL® (etanercept) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the C_H 2 domain, the C_H 3 domain and hinge region, but not the C_H 1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.

ENBREL® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL® can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL® is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs.

ENBREL® is indicated for reducing signs and symptoms and inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis. ENBREL® can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL® is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL® is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

ENBREL NEWS HIGHLIGHTS

Media Articles Related to Enbrel (Etanercept)

Study Showed Half Of Patients Treated With Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission
Source: Arthritis / Rheumatology News From Medical News Today [2008.07.20]

FDA Panel Recommends Enbrel for Pediatric Patients
Source: MedicineNet Juvenile Arthritis Specialty [2008.06.19]

Combo Drug Treatment Scores for Early Rheumatoid Arthritis
Source: MedPage Today Radiology [2008.07.15]

Improved Rheumatoid Arthritis Remission With Combined Therapy
Source: Arthritis / Rheumatology News From Medical News Today [2008.07.18]

more>>

Published Studies Related to Enbrel (Etanercept)

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. [2008.07]

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. [2008.07]

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. [2008.05]

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. [2008.05]

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. [2008.05]

more>>

Clinical Trials Related to Enbrel (Etanercept)

Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy [Completed]

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant [Active, not recruiting]

Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes [Completed]

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis [Terminated]

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris [Completed]

more>>